SCHEMBL2747489

SCHEMBL2747489

CC(C)(C)OC(=O)N1CC(C)(C)c2ccc(N)cc21.CC(C)(C)OC(=O)N1CC(C)(C)c2ccc(N)cc21

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.47
KDM1A O60341 1/20 0.41
NOTUM Q6P988 1/20 0.40
CNR2 P34972 1/20 0.34
ESR2 Q92731 1/20 0.34
XIAP P98170 4/20 0.34
BIRC2 Q13490 4/20 0.34
BUB1 O43683 1/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC1 Q13547 1/20 0.34
SMARCA2 P51531 1/20 0.33
SMARCA4 P51532 1/20 0.33
PBRM1 Q86U86 1/20 0.33
BCHE P06276 1/20 0.33
CYP11B2 P19099 1/20 0.33
BRD4 O60885 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
HSD17B3 P37058 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2746878 1.00 NR1H2 (0.47) NR1H2KDM1ANOTUMCNR2ESR2
SCHEMBL29984113 1.00 NR1H2 (0.47) NR1H2KDM1ANOTUMCNR2ESR2
SCHEMBL399420 0.87 NR1H2 (0.51) NR1H2KDM1AESR2BUB1HDAC2
SCHEMBL17252097 0.86 NR1H2 (0.49) NR1H2KDM1ANOTUMESR2XIAP
SCHEMBL13734404 0.85 NOTUM (0.41) NR1H2KDM1ANOTUMCNR2ESR2
SCHEMBL2306195 0.85 NOTUM (0.43) NOTUMCNR2XIAPBIRC2BRD4
SCHEMBL13733409 0.84 XIAP (0.48) KDM1ANOTUMESR2XIAPBIRC2
SCHEMBL17252191 0.84 NR1H2 (0.44) NR1H2KDM1ANOTUMESR2XIAP
SCHEMBL14568588 0.83 NOTUM (0.41) NOTUMCNR2XIAPBIRC2
SCHEMBL2559033 0.82 NOTUM (0.39) NR1H2KDM1ANOTUMCNR2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET NR1H2 986/4885KDM1A 4467/4885NOTUM 1151/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET NR1H2 986/4885KDM1A 4467/4885NOTUM 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.